Dysregulated bioenergetics: a key regulator of joint inflammation.

Biniecka MCanavan MMcGarry TGao WMcCormick JCregan SGallagher LSmith TPhelan JJRyan JO’Sullivan JNg CTVeale DJFearon U.Ustekinumab for the treatment of refractory giant cell arteritis.

Conway R, O’Neill L, O’Flynn E, Gallagher P, McCarthy GM, Murphy CC, Veale DJ, Fearon U, Molloy ES. Ann Rheum Dis. 2016 Aug;75(8):1578-9.

Hypoxia, mitochondrial dysfunction and synovial invasiveness in rheumatoid arthritis.

Fearon U, Canavan M, Biniecka M, Veale DJ. Nat Rev Rheumatol. 2016 Jul;12(7):385-97.

Acute serum amyloid A is an endogenous TLR2 ligand that mediates inflammatory and angiogenic mechanisms.

Connolly M, Rooney PR, McGarry T, Maratha AX, McCormick J, Miggin SM, Veale DJ, Fearon U. Ann Rheum Dis. 2016 Jul;75(7):1392-8.

A clinically based protein discovery strategy to identify potential biomarkers of response to anti-TNF-α treatment of psoriatic arthritis.

Collins ES, Butt AQ, Gibson DS, Dunn MJ, Fearon U, van Kuijk AW, Gerlag DM, Pontifex E, Veale DJ, Tak PP, FitzGerald O, Pennington SR. Proteomics Clin Appl. 2016 Jun;10(6):645-62.

Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis.

Ademowo OS, Hernandez B, Collins E, Rooney C, Fearon U, van Kuijk AW, Tak PP, Gerlag DM, FitzGerald O, Pennington SR.

Ann Rheum Dis. 2016 Jan;75(1):234-41